Stephany da Silva Costa

Stephany da Silva Costa

Auto-generated profile, based on publicly available information

Stephany da Silva Costa

DA - Laboratory of Biotechnology and Tissue Bioengineering, Federal University of Rio de Janeiro, LECC, SSC, Carlos Chagas Filho Biophysic Institute, CCS, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RPRaiane Dandara Pereira Pimentel
Raiane Dandara Pereira Pimentel
PCPriscila Goes Camargo
Priscila Goes Camargo
PAPedro Henrique R. de A. Azevedo
Pedro Henrique R. de A. Azevedo
LCLarissa Esteves Carvalho Constant
Larissa Esteves Carvalho Constant
SCStephany da Silva Costa
Stephany da Silva Costa
CLCamilo Lima
Camilo Lima
We investigated statin-based peptidomimetic compounds as inhibitors of SARS-CoV-2 papain-like protease (PLpro) by in silico methods, including molecular docking/dynamic simulations and ADMET prediction, as well as enzymatic in vitro assays. Five compounds (LQMed 426, 428, 430, 431, and 432) were identified as having promising interactions with the active site and an allosteric site of PLpro. The docking poses in the active site revealed that the compounds interacted with the catalytic triad (Cys111, His272, and Asp286). Compound 426 stood out for forming significant hydrophobic interactions and hydrogen bonds. In molecular dynamic (MD) simulations, there was a tendency for the compounds to migrate to a pocket in the ubiquitin-like (Ubl) domain region, indicating possible allosteric inhibition. Principal component analysis (PCA) and free energy landscape (FEL) plot showed significant differences in the conformational stability of protein-ligand complexes. Complex 432 had the highest stability (PC1: 24.9%, PC2: 10.5%) with restricted movements, while complex 430 had the lowest stability and the highest PC1, indicating broader movements. Complexes 426 and 428 had intermediate stability. FEL analysis confirmed that complex 432 had multiple minimum energy clusters, suggesting a greater likelihood of stable enzyme-ligand complex. In vitro assays demonstrated that all compounds inhibited PLpro activity by at least 50%, with IC50 values ranging from 0.85 µM to 4.06 µM. Compounds 426 and 432 were the most promising, with IC50 of 0.85 µM and 1.46 µM, respectively, values comparable to the GRL-0617 reference inhibitor. Binding free energy analysis indicated that compounds 430 and 431 showed significant affinity for the allosteric site (-27 kcal/mol and − 14 kcal/mol, respectively), while compound 428 showed reduced stability. In addition, in silico pharmacokinetics and toxicity (ADMET) prediction revealed that statine-based compounds are promising compared to GRL-0617 due to the low potential of inhibition of CYP’s family and toxicity risk. Overall, the tested compounds, especially 426 and 432, showed potential as inhibitors of SARS-CoV-2 PLpro and may act by non-competitive or mixed mechanisms, making them promising candidates for developing antivirals against CoViD-19.